Sorrento Therapeutics, a biopharmaceutical company, use Obducat’s NIL technology to fabricate the nanotopography draped microneedles used in the Sofusa® Drug Delivery System.
Sorrento Therapeutics reports positive initial result in dosing of first enbrel-non-responding rheumatoid arthritis patient with the Sofusa® Lymphatic Drug Delivery Device.
Sorrento reports that this is the first in-human Sofusa lymphatic delivery of a large molecule biologic for treatment. Additional immune-oncology trials with checkpoint inhibitors such as anti-PD1 and anti-CTLA4 antibodies are in place for solid tumors. The first patient, who was a non-responder to Enbrel subcutaneous injections treatment, had a DAS28 score equal to 4.6, with a swollen joint count of 7 and tender joints of 11. After 4 weekly doses of Sofusa-delivered Enbrel, the patient’s DAS28 score dropped by 33%, total swollen joint count by 29%, and tender joint count by 45%, without any serious adverse events or skin reactions observed.
Read more about Sorrento’s report on Positive Initial Result in Dosing of First Enbrel-Non-Responding Rheumatoid Arthritis Patient With the Sofusa® Lymphatic Drug Delivery Device by clicking below link:
Sorrento Reports Positive Initial Result in Dosing of First Enbrel-Non-Responding Rheumatoid Arthritis Patient With the Sofusa® Lymphatic Drug Delivery Device – Sorrento Therapeutics
Read more about the Sofusa Lymphatic Delivery System by clicking below link:
Lymphatic Delivery System – Sorrento Therapeutics